FNY Partners Fund LP bought a new stake in GW Pharmaceuticals PLC (NASDAQ:GWPH) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 1,800 shares of the biopharmaceutical company’s stock, valued at approximately $201,000.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Advisory Services Network LLC raised its position in shares of GW Pharmaceuticals PLC by 1,109.2% in the third quarter. Advisory Services Network LLC now owns 786 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 721 shares during the last quarter. Advisor Group Inc. raised its position in shares of GW Pharmaceuticals PLC by 58.2% in the third quarter. Advisor Group Inc. now owns 949 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 349 shares during the last quarter. Howard Hughes Medical Institute purchased a new position in shares of GW Pharmaceuticals PLC during the third quarter valued at $166,000. IFP Advisors Inc raised its position in shares of GW Pharmaceuticals PLC by 5.7% in the second quarter. IFP Advisors Inc now owns 1,859 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 100 shares during the last quarter. Finally, Doheny Asset Management CA purchased a new position in shares of GW Pharmaceuticals PLC during the second quarter valued at $250,000. 72.11% of the stock is currently owned by institutional investors.
Shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) traded up 0.23% during mid-day trading on Friday, hitting $128.23. The company’s stock had a trading volume of 284,593 shares. GW Pharmaceuticals PLC has a 1-year low of $35.83 and a 1-year high of $137.88. The company’s market cap is $3.23 billion. The company has a 50-day moving average of $118.49 and a 200 day moving average of $111.91.
GW Pharmaceuticals PLC (NASDAQ:GWPH) last released its earnings results on Tuesday, February 7th. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.69) by $0.92. The business had revenue of $2.54 million for the quarter, compared to the consensus estimate of $1.85 million. GW Pharmaceuticals PLC had a negative return on equity of 20.07% and a negative net margin of 702.90%. GW Pharmaceuticals PLC’s quarterly revenue was down 32.4% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.06) earnings per share. On average, analysts expect that GW Pharmaceuticals PLC will post ($3.83) EPS for the current year.
TRADEMARK VIOLATION NOTICE: “1,800 Shares in GW Pharmaceuticals PLC (GWPH) Acquired by FNY Partners Fund LP” was originally published by sleekmoney and is the sole property of of sleekmoney. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at http://sleekmoney.com/1800-shares-in-gw-pharmaceuticals-plc-gwph-acquired-by-fny-partners-fund-lp/1656060.html.
Several research analysts have weighed in on GWPH shares. Cowen and Company set a $135.00 target price on GW Pharmaceuticals PLC and gave the stock a “buy” rating in a research report on Monday, February 6th. Piper Jaffray Companies set a $147.00 price objective on GW Pharmaceuticals PLC and gave the company a “buy” rating in a report on Tuesday. Cantor Fitzgerald set a $208.00 price objective on GW Pharmaceuticals PLC and gave the company a “buy” rating in a report on Tuesday. Goldman Sachs Group, Inc. (The) started coverage on GW Pharmaceuticals PLC in a report on Friday, January 13th. They set a “buy” rating and a $189.00 price objective on the stock. Finally, Leerink Swann reissued a “buy” rating and set a $162.00 price objective on shares of GW Pharmaceuticals PLC in a report on Thursday, November 3rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. GW Pharmaceuticals PLC presently has an average rating of “Buy” and a consensus price target of $147.13.
GW Pharmaceuticals PLC Company Profile
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
Want to see what other hedge funds are holding GWPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GW Pharmaceuticals PLC (NASDAQ:GWPH).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/1800-shares-in-gw-pharmaceuticals-plc-gwph-acquired-by-fny-partners-fund-lp/1656060.html
Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.